Medicines Australia and AMA set out federal election priorities, including PBS and MBS

11 August 2010

Ahead of the federal elections due to take place in Australia on .August 21, the research-based drug trade group Medicines Australia and the Australian Medical Association have set out their wish lists for government action, whoever wins.

Medicines Australia chief executive Brendan Shaw yesterday announced the 2010 federal election priorities for the Australian medicines industry, urging all political parties to support three key objectives:

' Provide business certainty for the Australian medicines industry
' Ensure Australian medicines industry innovation remains internationally competitive
' Deliver better access, information and opportunities associated with the PBS listing of medicines.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >